A Randomized Study of the Relative Bioavailability, Pharmacodynamics, Safety of SAR236553 (REGN727) After Single Subcutaneous Administration at 3 Different Injection Sites in Healthy Subjects
A Randomized Study of the Relative Bioavailability, Pharmacodynamics, Safety of SAR236553 (REGN727) After Single Subcutaneous Administration at 3 Different Injection Sites in Healthy Subjects
Primary Objective:
To assess the relative bioavailability of a single subcutaneous dose of alirocumab SAR236553 (REGN727) administered at 3 different injection sites in healthy subjects.
Secondary Objectives:
Total duration of the study per subject is about 15 weeks.
Inclusion criteria:
Healthy subjects.
Exclusion criteria:
Healthy subjects with history or presence of clinically relevant illness.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.